3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company."The company has a blockbuster drug that's funding its pipeline efforts. Its shares are up more than 20% over the past year and up more than 97% over the past five years.There are plenty of reasons why the stock could continue to deliver market-beating returns, the biggest being a growing pipeline that will soon diversify its oncology treatment offerings. Here are three.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool